Aurobindo Pharma Limited (AUROPHARMA) - Total Liabilities
Based on the latest financial reports, Aurobindo Pharma Limited (AUROPHARMA) has total liabilities worth Rs206.19 Billion INR (≈ $2.23 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Aurobindo Pharma Limited equity growth rate to track the company's year-over-year net asset growth rate.
Aurobindo Pharma Limited - Total Liabilities Trend (2004–2026)
This chart illustrates how Aurobindo Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. See Aurobindo Pharma Limited (AUROPHARMA) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Aurobindo Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Aurobindo Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SailPoint, Inc. Common Stock
NASDAQ:SAIL
|
USA | $751.33 Million |
|
Anglo American Platinum Ltd
JSE:AMS
|
South Africa | ZAC68.83 Billion |
|
Shandong Sinocera Func Material
SHE:300285
|
China | CN¥2.24 Billion |
|
Zhengzhou Yutong Bus Co Ltd
SHG:600066
|
China | CN¥17.37 Billion |
|
Modine Manufacturing Company
NYSE:MOD
|
USA | $1.35 Billion |
|
Cytokinetics Inc
NASDAQ:CYTK
|
USA | $2.10 Billion |
|
Accor S. A.
PA:AC
|
France | €7.03 Billion |
|
Symrise AG
F:SY1
|
Germany | €4.16 Billion |
Liability Composition Analysis (2004–2026)
This chart breaks down Aurobindo Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Aurobindo Pharma Limited.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aurobindo Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aurobindo Pharma Limited (2004–2026)
The table below shows the annual total liabilities of Aurobindo Pharma Limited from 2004 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs206.19 Billion ≈ $2.23 Billion |
+20.31% |
| 2025-03-31 | Rs171.38 Billion ≈ $1.85 Billion |
+12.60% |
| 2024-03-31 | Rs152.21 Billion ≈ $1.65 Billion |
+16.74% |
| 2023-03-31 | Rs130.38 Billion ≈ $1.41 Billion |
+39.48% |
| 2022-03-31 | Rs93.48 Billion ≈ $1.01 Billion |
-21.61% |
| 2021-03-31 | Rs119.25 Billion ≈ $1.29 Billion |
-1.47% |
| 2020-03-31 | Rs121.03 Billion ≈ $1.31 Billion |
-3.65% |
| 2019-03-31 | Rs125.62 Billion ≈ $1.36 Billion |
+33.37% |
| 2018-03-31 | Rs94.19 Billion ≈ $1.02 Billion |
+36.99% |
| 2017-03-31 | Rs68.75 Billion ≈ $743.55 Million |
-24.47% |
| 2016-03-31 | Rs91.02 Billion ≈ $984.40 Million |
+17.71% |
| 2015-03-31 | Rs77.33 Billion ≈ $836.27 Million |
+35.33% |
| 2014-03-31 | Rs57.14 Billion ≈ $617.95 Million |
+22.72% |
| 2013-03-31 | Rs46.56 Billion ≈ $503.54 Million |
+19.76% |
| 2012-03-31 | Rs38.88 Billion ≈ $420.45 Million |
+13.57% |
| 2011-03-31 | Rs34.23 Billion ≈ $370.22 Million |
+15.73% |
| 2010-03-31 | Rs29.58 Billion ≈ $319.89 Million |
-0.81% |
| 2009-03-31 | Rs29.82 Billion ≈ $322.50 Million |
+18.94% |
| 2008-03-31 | Rs25.07 Billion ≈ $271.15 Million |
-4.19% |
| 2007-03-31 | Rs26.17 Billion ≈ $283.01 Million |
+39.78% |
| 2006-03-31 | Rs18.72 Billion ≈ $202.47 Million |
+32.28% |
| 2005-03-31 | Rs14.15 Billion ≈ $153.06 Million |
+24.05% |
| 2004-03-31 | Rs11.41 Billion ≈ $123.39 Million |
-- |
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system,… Read more